Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice-Reference-Cited by-同舟云学术

Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice

Published:2013-10 Issue:10 Volume:21 Page:1909-1918
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Rodríguez-Lebrón Edgardo,Costa Maria doCarmo,Luna-Cancalon Katiuska,Peron Therese M,Fischer Svetlana,Boudreau Ryan L,Davidson Beverly L,Paulson Henry L

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference37 articles.

1. Toward understanding Machado-Joseph disease;Costa Mdo;Prog Neurobiol,2012

2. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease;Matos;Prog Neurobiol,2011

3. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond;Durr;Lancet Neurol,2010

4. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3;Boy;Hum Mol Genet,2009

5. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease;Yamamoto;Cell,2000

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAG repeat-selective compounds reduce abundance of expanded CAG RNAs in patient cell and murine models of SCAs;2024-08-17

2. Emerging therapies in hereditary ataxias;Trends in Molecular Medicine;2024-08

3. Quantification of Solid Embryonic Cerebellar Graft Volume in a Degenerative Ataxia Model;The Cerebellum;2024-03-02

4. Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?;Cells;2024-02-09

5. Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3;Disease Models & Mechanisms;2023-09-01